Radium-223 in mCPRC patients: a large real-life Italian multicenter study

Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration.



Titolo: Radium-223 in mCPRC patients: a large real-life Italian multicenter study
Autori: 
SPANU, Angela
NUVOLI, Susanna Maria Francesca
mostra contributor esterni 
Data di pubblicazione: 2020
Rivista: 
MINERVA UROLOGICA E NEFROLOGICA  
Abstract: Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration.
Handle: http://hdl.handle.net/11388/237887
Appare nelle tipologie:1.1 Articolo in rivista

File in questo prodotto:
Non ci sono file associati a questo prodotto.
Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11388/237887
  • Citazioni
  • PubMed Central ND
  • Scopus ND
  • WOS ND

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2021